International Trial Opens for Bundibugyo Virus Disease Treatment Evaluation
In a major international effort to evaluate potential treatments for Ebola disease caused by the Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.
The PARTNERS trial will assess whether two antiviral therapies – a monoclonal antibody (MBP134) and remdesivir – can improve survival among people diagnosed with BVD. It will also evaluate whether combining the two antivirals provides additional benefits.
Since the outbreak began, over 1400 people have been diagnosed with BVD, nearly 210 have recovered, and around 440 have died in the Democratic Republic of the Congo.
The trial was selected by the WHO Technical Advisory Group after reviewing scientific evidence, including preclinical research and safety data.
People enrolled in the clinical trial will receive close support and follow-up for at least 28 days after enrolment.
